Low T3 signaling raises LDL cholesterol by reducing hepatic LDL receptor expression.

Thyroid hormone (T3) is a central regulator of lipid metabolism, exerting a powerful influence on how the liver processes and clears cholesterol from the bloodstream. Insufficient T3 signaling is a well-established driver of elevated low-density lipoprotein (LDL) cholesterol.

Clinical and effectiveness evidence

The relationship between T3 levels and LDL cholesterol is robustly supported by clinical observations in both hypothyroid and euthyroid populations.

• LDL Reduction: Interventional studies demonstrate that T3 supplementation can reduce circulating LDL cholesterol by approximately 13.3% in clinical settings.
• Inverse Correlation: In patients with low T3 states, such as non-thyroidal illness syndrome or clinical hypothyroidism, there is a strong and consistent correlation between low free T3 levels and elevated serum LDL cholesterol.
• Clearance Rates: Clinical data confirm that the hypercholesterolemia associated with low thyroid function is primarily due to a decreased fractional catabolic rate of LDL—meaning the body removes LDL particles from the blood much more slowly than normal.

Mechanistic explanations

The primary mechanism by which T3 regulates LDL cholesterol is through the modulation of hepatic LDL receptor (LDLR) expression and trafficking.

• Direct Gene Transcription: T3 binds to the thyroid hormone receptor $\beta$1 (TR$\beta$1) in the liver. This complex binds directly to thyroid response elements (TREs) on the LDLR gene promoter (specifically at positions -612 and -156), triggering the production of mRNA and the subsequent synthesis of LDLR proteins.
• Receptor Trafficking: Beyond just producing more receptors, T3 ensures they function correctly. It promotes the proper intracellular trafficking of LDLR via the CCC/WASH protein complex. In low T3 states, these receptors are often misdirected to lysosomes for degradation rather than being recycled to the cell surface, further impairing LDL clearance.
• Bile Acid Synthesis: T3 influences the conversion of cholesterol into bile acids by regulating the rate-limiting enzyme CYP7A1. While this effect is direct and clear in animal models, human data are more complex; however, T3 consistently increases the overall flux of cholesterol through the liver toward biliary excretion, providing a secondary pathway for lowering systemic cholesterol.

Safety and physiological considerations

Because T3 acts independently of the sterol regulatory element-binding protein (SREBP) system—the body's primary cholesterol-sensing mechanism—it can stimulate LDL clearance even when intracellular cholesterol levels are already high. This makes the T3-LDLR pathway a unique and potent target for lipid regulation. Conversely, when T3 signaling is low, the liver loses this critical stimulatory signal, leading to a predictable rise in circulating LDL.

Bottom line

Low T3 signaling directly raises LDL cholesterol by reducing the expression and trafficking of hepatic LDL receptors, which significantly impairs the clearance of LDL particles from the blood. While T3 also influences bile acid synthesis to promote cholesterol excretion, its primary impact on lipid profiles is driven by this LDLR-mediated clearance mechanism.